DBV Technologies S.A
Health Care · USD
Price
$20.59
Cap
$1.1B
Earnings
0/1 beat
30d Trend
-4%
Upper half of range — momentum is positive
Target range: $7.25 – $51 (consensus: $38.65)
Consensus: Buy
Earnings history
Q4 2025
MISS
-1.15 vs -0.19
Key macro factors
Regulatory environment for biopharmaceutical products, including FDA approvals, which are critical for market entry and revenue generation.
Funding and investor sentiment in the biotech sector, as clinical-stage companies rely on external capital for R&D and operations.
Competition within the allergy treatment market, affecting the commercial success of new products like the Viaskin Peanut patch.
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France, and its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.